Search results for Abbvie

<![CDATA[Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement]]>

<![CDATA[Haisco Enters $745 Million Exclusive License Agreement with AbbVie ]]>

Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind

The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, but the biotech’s stock jumped in premarket trading.

<![CDATA[Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie]]>

AbbVie Oncology

AbbVie Oncology Anonymous (not verified) Tue, 04/07/2026 - 20:01 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

<![CDATA[AbbVie Invests $1.4 Billion into New Manufacturing Campus in North Carolina ]]>

Two Paths to Growth: Johnson & Johnson vs AbbVie

AbbVie: Upside Potential And Dividends With Competent Portfolio Renewal

AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit

AbbVie is spearheading a new battle in pharma's long-running fight to reform the federal government’s 340B drug discount program.

AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets

AbbVie has agreed to pay $30 million upfront to Chinese biotech Haisco Pharmaceutical Group for two non-opioid pain treatment candidates.

AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer

AbbVie drug Decnupaz received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This antibody drug conjugate came from AbbVie’s 2023 ImmunoGen acqui...

<![CDATA[FDA Issues CRL to AbbVie for TrenibotulinumtoxinE’s Biologics License Application ]]>

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus

The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.

BeiGene Must Face AbbVie's Chemical Trade Secret Claims

An Illinois federal judge has denied oncological research company BeiGene's request to escape claims from AbbVie Inc. that it poached a retired scientist to obtain trade secrets re...

AbbVie wrinkle treatment rejected by FDA over manufacturing issues

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>

AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1.45 billion in value and end with AbbVie buying the company outright.

MSLs at Abbvie

MSLs at Abbvie Anonymous (not verified) Wed, 04/29/2026 - 14:17 field_thread_url https://cafepharma.com/boards/threads/msls-at-abbvie.668170/...

Spotlight On: Humira® (adalimumab) / Amjevita™ (adalimumab-atto) / Cyltezo® (adalimumab-adbm) / Hyrimoz™ (adalimum...

Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the...

Spotlight On: Humira® (adalimumab) / Amjevita™ (adalimumab-atto) / Cyltezo® (adalimumab-adbm) / Hyrimoz™ (adalimum...

Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the...

<![CDATA[Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal]]>

Why AbbVie Is a No-Brainer Stock to Buy on the Dip

The pharma giant is still a rock-solid dividend stock.